Maise Al Bakir/crick.ac.uk
Feb 22, 2025, 13:10
Why immunotherapy has struggled in EGFR+ lung cancer – EGFR Positive Lung Cancer UK
EGFR Positive Lung Cancer UK shared an article by Maise Al Bakir, et al. on X:
“NEW Nature study helps explain why immunotherapy has struggled in EGFR+ lung cancer.
Research shows tumours can change under TKI treatment & immune pressure, losing markers that help the immune system recognise them.”
Clonal driver neoantigen loss under EGFR TKI and immune selection pressures.
Authors: Maise Al Bakir, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 10, 2025, 06:53
Jul 9, 2025, 23:47
Jul 9, 2025, 23:31
Jul 9, 2025, 23:14
Jul 9, 2025, 23:06
Jul 9, 2025, 22:41